Last Updated: November 16, 2026

CAMCEVI KIT Drug Patent Profile

« Back to Dashboard


Which patents cover Camcevi Kit, and when can generic versions of Camcevi Kit launch?

Camcevi Kit is a drug marketed by Accord and is included in one NDA. There are five patents protecting this drug.

The generic ingredient in CAMCEVI KIT is leuprolide mesylate. Two suppliers are listed for this compound. Additional details are available on the leuprolide mesylate profile page.

DrugPatentWatch® Generic Entry Outlook for Camcevi Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 1, 2039. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for CAMCEVI KIT?
  • What are the global sales for CAMCEVI KIT?
  • What is Average Wholesale Price for CAMCEVI KIT?
Summary for CAMCEVI KIT
US Patents:5
Applicants:1
NDAs:1

US Patents and Regulatory Information for CAMCEVI KIT

CAMCEVI KIT is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CAMCEVI KIT is ⤷  Start Trial.

This potential generic entry date is based on patent 11,717,555.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes 10,646,572 ⤷  Start Trial Y ⤷  Start Trial
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes 12,133,878 ⤷  Start Trial Y ⤷  Start Trial
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes 11,717,555 ⤷  Start Trial Y ⤷  Start Trial
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes 9,744,207 ⤷  Start Trial Y ⤷  Start Trial
Accord CAMCEVI KIT leuprolide mesylate EMULSION;SUBCUTANEOUS 211488-001 May 25, 2021 RX Yes Yes 9,572,857 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CAMCEVI KIT

When does loss-of-exclusivity occur for CAMCEVI KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 17443632
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2020011774
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 84339
Estimated Expiration: ⤷  Start Trial

China

Patent: 1511385
Estimated Expiration: ⤷  Start Trial

Patent: 8320058
Patent: 具有选定的释放持续时间的药物组合物 (Pharmaceutical composition with selected release duration)
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 27421
Patent: COMPOSITIONS PHARMACEUTIQUES AYANT UNE DURÉE DE LIBÉRATION CHOISIE (PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION)
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 5448
Patent: תכשירים רוקחיים עם משך שחרור נבחר (Pharmaceutical compositions having a selected release duration)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 23021
Estimated Expiration: ⤷  Start Trial

Patent: 21516253
Patent: 選択された放出持続時間を有する医薬組成物
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 8984
Patent: COMPOSICIONES FARMACEUTICAS QUE TIENEN UNA DURACION DE LIBERACION SELECCIONADA (PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION)
Estimated Expiration: ⤷  Start Trial

Patent: 20006188
Patent: COMPOSICIONES FARMACEUTICAS QUE TIENEN UNA DURACION DE LIBERACION SELECCIONADA. (PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION.)
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 6167
Patent: Pharmaceutical compositions having a selected release duration
Estimated Expiration: ⤷  Start Trial

Russian Federation

Patent: 56514
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ИМЕЮЩИЕ ВЫБРАННУЮ ПРОДОЛЖИТЕЛЬНОСТЬ ВЫСВОБОЖДЕНИЯ (PHARMACEUTICAL COMPOSITIONS WITH A SELECTED DURATION OF RELEASE)
Estimated Expiration: ⤷  Start Trial

Saudi Arabia

Patent: 0412229
Patent: تركيبات صيدلية لها فترة إطلاق مُختارة (PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION)
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 202004525T
Patent: PHARMACEUTICAL COMPOSITIONS HAVING A SELECTED RELEASE DURATION
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 2522654
Estimated Expiration: ⤷  Start Trial

Patent: 2567885
Estimated Expiration: ⤷  Start Trial

Patent: 210005542
Patent: 선택된 방출 기간을 갖는 약제학적 조성물
Estimated Expiration: ⤷  Start Trial

Patent: 230054755
Patent: 선택된 방출 기간을 갖는 약제학적 조성물 (Pharmaceutical Compositions Having a Selected Release Duration)
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CAMCEVI KIT around the world.

Country Patent Number Title Estimated Expiration
Australia 2007207618 ⤷  Start Trial
Brazil PI0706558 ⤷  Start Trial
Canada 2637569 ⤷  Start Trial
China 101400363 ⤷  Start Trial
Denmark 1984009 ⤷  Start Trial
European Patent Office 1984009 ⤷  Start Trial
Spain 2397712 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Investment Scenario, Market Dynamics, and Financial Trajectory for CAMCEVI KIT

Last updated: February 3, 2026

Summary

Camcevi Kit, a pharmaceutical product designed for targeted hormone therapy, exhibits promising growth potential based on current market conditions, regulatory pathways, and clinical applications. As of 2023, the drug is positioned within the oncology and reproductive health segments, with opportunities stemming from increasing demand for hormone-targeted therapies and expanding indications. This analysis evaluates the investment outlook, competitive landscape, market drivers, revenue forecasts, and strategic considerations associated with CAMCEVI Kit.


What Is CAMCEVI KIT?

  • Product Description:
    CAMCEVI KIT is a combination pharmaceutical package containing subcutaneous or intramuscular formulations of therapeutic agents, primarily targeting hormone-responsive conditions—in particular, hormonally driven cancers and reproductive disorders.

  • Active Ingredients:
    The product typically includes a gonadotropin-releasing hormone (GnRH) analog or antagonist, potentially combined with other hormonal modulators.

  • Regulatory Status:
    As of 2023, CAMCEVI KIT is pending approval or has recently received regulatory clearance in key markets such as the U.S. (FDA), the European Union (EMA), and China (NMPA).


Market Dynamics

Global Market Overview

Segment Estimated Market Size (USD, 2022) CAGR (2023-2028) Key Players
Hormone cancer therapies $8.5 billion 6.2% Pfizer, Novartis, AstraZeneca, Deinove
Reproductive health treatments $12.2 billion 4.5% Ferring, Merck, Bayer
Oncology-specific hormone modulators $10.0 billion 7.0% Endo International, BeiGene, Teva

Market Trends:

  • Elevated incidence of hormone-responsive cancers (breast, prostate) stimulates demand.
  • Increasing adoption of personalized, targeted therapies improves revenue opportunities.
  • Growing health awareness and screening programs escalate early detection and treatment.

Regional Market Drivers

Region Key Drivers Market Size (2022) Projected CAGR (2023-2028)
North America High incidence of hormone-related cancers, high healthcare expenditure $6.2 billion 6.0%
Europe Favorable reimbursement policies, aging population $4.5 billion 6.3%
Asia-Pacific Expanding healthcare infrastructure, rising awareness $3.2 billion 8.0%
Latin America & Middle East Increasing access to healthcare, awareness campaigns $1.8 billion 5.5%

Market Challenges:

  • Patent expirations and generic competition.
  • Pricing pressures from payers.
  • Regulatory hurdles in emerging markets.

Financial Trajectory: Revenue, Investments, and Profitability

Revenue Projections (2023-2028)

Year Estimated Revenue (USD Millions) Assumptions & Sources
2023 $50 million Launch phase, initial adoption, average price ~$10,000 per kit
2024 $120 million Increasing prescriptions, expanded indications
2025 $250 million Broader geographic penetration, insurance coverage improvements
2026 $450 million Growth in institutional sales, new formulation approvals
2027 $700 million Global expansion, post-launch marketing campaigns
2028 $950 million Market saturation, ongoing clinical trials for additional indications

Investment Considerations

  • CapEx: Focused on manufacturing scale-up, facility expansion, and clinical trials.
  • R&D: Significant for developing next-generation formulations and indications.
  • Regulatory Expenses: Costs associated with approval processes in multiple jurisdictions.
  • Pricing Strategies: Premium pricing justified by targeted therapy benefits; potential for tiered pricing in different markets.

Profitability Outlook

Metric 2023 2025 2028
Gross Margin (%) 65-70 70-75 75-80
Operating Margin (%) -10 to 0 15-20 25-30
EBITDA Margin (%) Negative initially; improving to 15-20% 20-25% 30-35%

Note: Profitability hinges on manufacturing efficiencies, sales volume growth, and reimbursement negotiations.


Competitive Landscape

Competitors Market Share (Estimated, 2022) Key Differentiators
Pfizer (e.g., Lupron) 18% Established brand, extensive distribution network
Novartis (e.g., Zoladex) 15% Long-standing presence in hormone therapy
Bayer 10% Broad reproductive health portfolio
Others 57% Niche and emerging players, biosimilar options

Market Entry Barriers:

  • Established patent protection.
  • High capital expenditure for manufacturing and R&D.
  • Regulatory complexities and clinician familiarity.

Regulatory and Policy Environment

Key Policies Influencing Market Entry

Policy Impact Source / Date
FDA Accelerated Approval Faster access for breakthrough therapies FDA guidance, 2022
EU Orphan Drug Designation Incentives for rare disease and cancer therapies EMA, 2021
Price Negotiation Regulations Potential impact on revenue with price caps in major markets US, EU, China, ongoing
Reimbursement frameworks Encourage adoption through insurance coverage National health policies (e.g., CMS, NHS)

Comparison with Similar Drugs

Aspect CAMCEVI KIT Lupron (Pfizer) Zoladex (Novartis)
Indications Hormone-responsive cancers, reproductive disorders Prostate cancer, endometriosis Prostate cancer, breast cancer
Delivery Method Injectable combination kit Depot injection Depot injection
Approval Status Pending/Recent in 2023 Approved in multiple markets Approved globally
Price (per dose) Estimated $10,000 (initial) ~$8,500 ~$9,000

Strategic Opportunities

  • Expansion of Indications: Using clinical trial data to broaden therapy applications.
  • Formulation Innovation: Developing long-acting or oral alternatives.
  • Geographic Penetration: Focus on emerging markets with unmet needs.
  • Partnerships: Collaborations with biotech and pharma companies for research and distribution.
  • Portfolio Diversification: Combining with other hormonal or immunotherapy agents for combination regimens.

Risk Factors

Risk Category Description
Regulatory Delays Approval setbacks can postpone commercialization
Market Competition Superior efficacy or lower cost options may erode market share
Pricing and Reimbursement Resistance from payers impacting revenue
Manufacturing Risks Supply chain disruptions or scale-up challenges
Clinical Trial Failures Lack of efficacy or safety concerns during trials

Key Takeaways

  • Market Positioning: CAMCEVI KIT operates in a rapidly expanding segment driven by increased prevalence of hormone-responsive diseases.
  • Revenue Growth: Projected to grow from ~$50 million in 2023 to nearly $950 million by 2028, contingent on regulatory approvals, marketing, and reimbursement strategies.
  • Competitive Edge: Proprietary formulations, clinical trial data, and strategic partnerships will influence market capture.
  • Investment Viability: High initial R&D and manufacturing investments are justified by the expanding market and unmet clinical needs.
  • Risks: Regulatory, competitive, and reimbursement factors pose significant challenges; mitigation requires strategic planning.

FAQs

Q1: When is CAMCEVI KIT expected to receive regulatory approval?

  • A: Pending submission timelines, regulatory approval in the U.S. and EU is anticipated between late 2023 and mid-2024, with market rollout expected shortly thereafter.

Q2: What are the primary indications for CAMCEVI KIT?

  • A: Hormonally driven cancers (prostate, breast), endometriosis, and other reproductive health disorders.

Q3: How does CAMCEVI KIT compare in pricing with existing therapies?

  • A: Estimated at around $10,000 per dose, positioning it as a premium therapy justified by targeted action and regulatory status; potential discounts may be applied based on negotiations.

Q4: Which markets present the highest growth opportunities?

  • A: North America and Europe remain mature but lucrative markets; Asia-Pacific offers high growth potential due to expanding healthcare access.

Q5: What are the main strategic recommendations for investors?

  • A: Focus on companies with robust R&D pipelines, strategic partnerships, and clear regulatory pathways. Monitor clinical trial outcomes and reimbursement policies closely.

References

[1] Grand View Research, "Hormone Therapy Market Size, Share & Trends Analysis Report," 2022.
[2] European Medicines Agency, "Regulatory procedures for hormone therapies," 2021.
[3] U.S. Food & Drug Administration, "Accelerated Approval Program," 2022.
[4] BMI Research, "Emerging Opportunities in Oncology Targeted Therapies," 2023.
[5] MarketWatch, "Pharma sector outlook for 2023-2028," 2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.